Immunotherapy plus chemotherapy before surgery for diffuse stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving a combination of immunotherapy (QL1706) and chemotherapy before surgery helps shrink diffuse-type stomach cancer more than chemotherapy alone. The goal is to improve the chance of successful surgery and better long-term outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diffuse-type stomach cancer (with at least half signet-ring cells) that can be removed with surgery, and it does not have the HER2 protein.
- You are between 18 and 75 years old, can care for yourself (ECOG 0-1), and are in generally good health.
- Your tumor is at a certain stage (T3-4a) but has not spread to distant organs, and a team of doctors agrees it can be fully removed.
- You have not had any previous chemotherapy, radiation, or surgery for this cancer, and you have not had immunotherapy before.
- You do not have serious heart, lung, or autoimmune disease, active infections (like hepatitis B or C), or other uncontrolled medical conditions.
- You are willing to use effective contraception and have a life expectancy of at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This clinical trial tests whether adding an immunotherapy drug called tislelizumab to chemotherapy before surgery is better than chemotherapy alone for people with a certain type of stomach cancer. The goal is to see if the combination helps shrink the tumor and improves the chance of successful surgery.
This trial tests a combination of immune therapy and chemotherapy given before surgery for stomach or esophagus-stomach cancer. The goal is to shrink the tumor to make surgery more effective and possibly improve outcomes.
This trial tests a combination of immunotherapy (QL1706) and chemotherapy before surgery for people with early-stage stomach cancer. The goal is to see if this approach shrinks the tumor and improves surgical outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether adding an immunotherapy drug (Iparomlimab and Tuvonralimab, combined as QL1706) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced stomach or gastroesophageal junction cancer that can be surgically removed.
Hear when a new Gastric Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.